Several law firms issue notices to Capricor Therapeutics, Inc. (NASDAQ: CAPR) investors about a pending securities class action and a deadline to seek lead-plaintiff status. The actions involve investors who bought or acquired Capricor securities during the defined class period from December 17, 2025 through July 26, 2026, inclusive. Different firms—such as Robbins Geller Rudman & Dowd LLP, Rosen Law Firm, Bronstein, Gewirtz & Grossman LLC, DJS Law Group, Schall, Brown & Schwartz LLP, and Kaplan Fox & Kilsheimer LLP—publicize their efforts and advise affected investors to consider participating.
The allegations described in the notices say that Capricor communicated that its Phase 3 HOPE-3 results were statistically significant while allegedly omitting that the final statistical analysis plan was reportedly rewritten shortly before unblinding and was allegedly never agreed to by the FDA. The firms also state that investors may apply to serve as lead plaintiff, with the deadline consistently reported as September 28, 2026. The notices seek to inform investors about procedural steps and potential rights in the litigation.
